On Thursday, Vertex Pharmaceuticals earned a positive adjustment to its Relative Strength (RS) Rating, from 68 to 74. Please ...

VertexPharma wants to transform the treatment of pain. An upcoming sciatica clinical trial readout will be pivotal.

Vertex has reached a key moment because the U.S. Food and Drug Administration (FDA) is reviewing its candidate, suzetrigine, ...

15 analysts have expressed a variety of opinions on Vertex Pharmaceuticals (NASDAQ:VRTX) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides ...

Citi has started coverage of Gilead Sciences (NASDAQ:GILD) and Vertex Pharmaceuticals (NASDAQ:VRTX) at buy saying the former will benefit from short-term growth of Biktarvy (bictegravir, emtricitabine ...

Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals VRTX. And retail traders should ...

Boston, Massachusetts-based Vertex Pharmaceuticals Incorporated (VRTX) develops and commercializes therapies for treating cystic fibrosis (CF). Valued at $128.7 billion by market cap ...

Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...